Showing results (121-130 of 186) with videos related to
Sort By:
Pageof 19
International Journal of Cancer|June 30, 2005
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriersCarey A Cullinane, Jan Lubinski, Susan L Neuhausen, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 29, 2011
Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriersSusan L Neuhausen, Sean Brummel, Yuan Chun Ding, et al.JAMA Oncology|February 29, 2024
MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJan Lubinski, Joanne Kotsopoulos, Pal Moller, et al.Breast Cancer Research : BCR|March 28, 2006
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriersEitan Friedman, Joanne Kotsopoulos, Jan Lubinski, et al.Cancer Research|July 9, 2009
Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriersTimothy R Rebbeck, Nandita Mitra, Susan M Domchek, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 15, 2021
Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort studyKelly M Morgan, Jada G Hamilton, Heather Symecko, et al.Nature Cancer|March 19, 2021
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancerAnita K Mehta, Emily M Cheney, Christina A Hartl, et al.JCO Oncology Practice|July 19, 2024
Subcutaneous vs Intravenous Trastuzumab/Pertuzumab: A Time and Motion Substudy of a Phase II Trial of Adjuvant Trastuzumab/Pertuzumab for Stage I HER2+ Breast Cancer (ADEPT trial)Adrienne G Waks, Emily L Chen, Noah Graham, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 21, 2012
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriersBrian S Finkelman, Wendy S Rubinstein, Sue Friedman, et al.Clinical Breast Cancer|September 28, 2019
Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022Rachel A Freedman, Rebecca S Gelman, Nathalie Y R Agar, et al.Pageof 19